Kelso & Company

Kelso & Company is a New York-based private equity firm with one of the longest operating histories in U.S. middle-market buyouts, leveraging deep sector expertise across multiple industries including healthcare. Healthcare exposure focuses on care delivery and tech-enabled services. AI is not a dedicated thesis, and Kelso’s brand is built on traditional control-oriented buyout investing. Specific AUM detail is not in the source data, but Kelso is a well-established middle-market sponsor.

Check sizes are $25M+ at the growth/buyout stage, with control investments dominant. Geographic deployment is primarily U.S. Specific healthcare portfolio companies are not listed in the source data. Diligence is heavy on management quality, defensible competitive position, and the firm’s ability to support multi-year operational improvement plans.

For founders, Kelso is relevant only at the upper end of the middle market. The right profile is the CEO of a healthcare services or platform business with substantial EBITDA and a track record of stable cash generation. Pre-revenue and early-stage AI builders are not the right fit. Kelso is best approached when the business is ready for a multi-year control ownership cycle.